GRTS
NASDAQGritstone bio Inc.
Latest news
25 items- 13D/GAmendment: SEC Form SC 13G/A filed by Gritstone bio Inc.SC 13G/A - Gritstone bio, Inc. (0001656634) (Subject)
- SECGritstone bio Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities8-K - Gritstone bio, Inc. (0001656634) (Filer)
- SECGritstone bio Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Regulation FD Disclosure8-K - Gritstone bio, Inc. (0001656634) (Filer)
- PRGritstone bio Takes Action to Preserve Value and Strengthen Capital StructureVoluntarily Files for Chapter 11 Restructuring Strategic Alternatives Process Continues with Interest from Parties Gritstone bio, Inc. (NASDAQ:GRTS) ("Gritstone" or the "Company"), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it has filed a voluntary petition under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Gritstone intends to use the court-administered restructuring process to preserve value and support its ongoing strategic alternatives process. The Company is in discussions with a party to act as a stalking horse bidder or plan sponsor and intends to
- 13D/GSEC Form SC 13G filed by Gritstone bio Inc.SC 13G - Gritstone bio, Inc. (0001656634) (Subject)
- ANALYSTGritstone bio downgraded by JMP SecuritiesJMP Securities downgraded Gritstone bio from Mkt Outperform to Mkt Perform
- SECSEC Form 8-K filed by Gritstone bio Inc.8-K - Gritstone bio, Inc. (0001656634) (Filer)
- PRGritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer--Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly --21% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.79 [95% CI, 0.42-1.50])-- -- 38% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.62 [95% CI, 0.23-1.70]) -- -- Strength of neoantigen specific T cell responses in GRANITE patients appears to associate with progression-free survival -- GRANITE was generally well-tolerated with no treatment discontinuations due to adverse events– -- Overa
- SECSEC Form 10-Q filed by Gritstone bio Inc.10-Q - Gritstone bio, Inc. (0001656634) (Filer)
- SECGritstone bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Gritstone bio, Inc. (0001656634) (Filer)
- PRGritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates-- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 -- -- Recent KOL event and patient advocacy engagements underscore the unmet need for new treatment options in metastatic colorectal cancer -- -- Presentations at AACR 2024 and ESCMID Global 2024 demonstrate the broad potential of Gritstone's oncology and infectious disease vaccines -- -- Cash, cash equivalents, marketable securities and restricted cash of $61.7 million as of June 30, 2024 -- EMERYVILLE, C
- PRGritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Potential Role of Its Personalized Cancer Vaccine, GRANITE, in Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)-- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) -- EMERYVILLE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced it will host a virtual key opinion leader (KOL) event on Friday, August 2 at 9:00 AM ET featuring J. Randolph Hecht, MD, (Professor, UCLA Gastrointestinal Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) who will discuss the unmet need and current treatment landscape for patients with metastatic microsatellite stable colorectal cancer (M
- PRGritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)EMERYVILLE, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the Compensation Committee of the company's Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 39,000 shares of its common stock with an exercise price of $0.57, which is equal to the closing price of Gritstone's common stock on July 3, 2024, the date of the grant. These stock options are part of an inducement material to the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options wil
- 13D/GAmendment: SEC Form SC 13G/A filed by Gritstone bio Inc.SC 13G/A - Gritstone bio, Inc. (0001656634) (Subject)
- INSIDERPRESIDENT AND CEO Allen Andrew R gifted 650,000 shares, decreasing direct ownership by 25% to 985,360 units (SEC Form 4)4 - Gritstone bio, Inc. (0001656634) (Issuer)
- SECSEC Form 8-K filed by Gritstone bio Inc.8-K - Gritstone bio, Inc. (0001656634) (Filer)
- SECSEC Form 8-K filed by Gritstone bio Inc.8-K - Gritstone bio, Inc. (0001656634) (Filer)
- INSIDERSEC Form 4 filed by Director Fisher Clare4 - Gritstone bio, Inc. (0001656634) (Issuer)
- INSIDERSEC Form 4 filed by Director Agarwal Shefali4 - Gritstone bio, Inc. (0001656634) (Issuer)
- INSIDERSEC Form 4 filed by Director Corey Lawrence4 - Gritstone bio, Inc. (0001656634) (Issuer)
- INSIDERSEC Form 4 filed by Director Rizvi Naiyer4 - Gritstone bio, Inc. (0001656634) (Issuer)
- INSIDERSEC Form 4 filed by Director Webster Stephen W4 - Gritstone bio, Inc. (0001656634) (Issuer)
- INSIDERSEC Form 4 filed by Director Jones Elaine V4 - Gritstone bio, Inc. (0001656634) (Issuer)
- NEWSForecasting The Future: 4 Analyst Projections For Gritstone BioDuring the last three months, 4 analysts shared their evaluations of Gritstone Bio (NASDAQ:GRTS), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 1 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $4.25, a high estimate of $5.00, and a low estimate of $3.00. This current average has decreased by 22.73% from the
- NEWSJMP Securities Reiterates Market Outperform on Gritstone Bio, Maintains $5 Price TargetJMP Securities analyst Roy Buchanan reiterates Gritstone Bio (NASDAQ:GRTS) with a Market Outperform and maintains $5 price target.
GRTS FAQ
7 questionsWhat does Gritstone bio Inc. do?
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer...Where does GRTS stock trade?
Gritstone bio Inc. (GRTS) is listed on NASDAQ.What sector and industry is GRTS in?
Gritstone bio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Gritstone bio Inc. go public?
Gritstone bio Inc. (GRTS) completed its IPO in 2018.What are analysts saying about GRTS?
Gritstone bio Inc. has had 8 recent analyst actions on file. The most recent action was from JMP Securities: Mkt Perform on 2024-10-01.What companies are similar to GRTS?
Notable peers in the same industry include ISEE (IVERIC bio Inc.), ABUS (Arbutus Biopharma Corporation), CABA (Cabaletta Bio Inc.), GRPH (Graphite Bio Inc.), GOSS (Gossamer Bio Inc.). Compare GRTS side-by-side with any of them on Quantisnow.How can I track GRTS on Quantisnow?
Quantisnow aggregates Gritstone bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GRTS to receive live email and push alerts on every new disclosure.